LMO4 (LIM domain only 4) is a transcriptional cofactor that regulates gene expression through protein-protein interactions rather than direct DNA binding 1. The protein functions by mediating the assembly of multiprotein complexes and shows nuclear retention enhanced by nuclear LIM interactor (NLI) 1. LMO4 plays diverse roles across different cell types: it establishes motor neuron identity by disrupting LDB1-LHX3 complexes [UniProt], enhances CD8+ T cell stemness by binding JAK1 and potentiating STAT3 signaling in response to IL-21 2, and regulates keratinocyte differentiation and proliferation through IL-23/AKT/STAT3 pathways 3. In disease contexts, LMO4 is overexpressed in more than 50% of primary breast cancers through increased promoter activity 4, promotes oral squamous cell carcinoma progression by inducing RAB17 degradation and ferroptosis resistance 5, and acts as a disease-provocative factor in psoriatic keratinocytes 3. The gene shows complex developmental expression patterns and appears to inhibit differentiation in mesenchymal tissues 1. Clinically, LMO4 overexpression correlates with poor prognosis in breast cancer and enhanced tumor progression in oral cancers, while its modulation shows therapeutic potential in T cell immunotherapies 25.